Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

University Hospital Basel

Status: Completed

Conditions: Neuroendocrine Tumors

Treatments: Diagnostic Test: Methylation analysis

Study type: Observational

Funder types: Other

Identifiers

NCT05013957

NEMESIs study

Details and patient eligibility

About

Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. The currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA represent a new, promising approach.

The aim of this project is therefore to improve the diagnostic and prognostic evaluation of neuroendocrine neoplasms by means of methylation analysis of the tumor DNA. On the one hand, existing tumor samples from the biobank of Basel University Hospital are evaluated, on the other hand, patients who are undergoing an operation will be prospectively inquired

Enrollment: 32 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• neuroendocrine tumor

Exclusion criteria

• insufficient amount or quality of neuroendocrine tumor sample

Trial design

32 participants in 2 patient groups

Retrospective analysis

Description:

Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated

Treatment:

Diagnostic Test: Methylation analysis

Prospective analysis

Description:

Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated

Treatment:

Diagnostic Test: Methylation analysis